Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update.
Hansoh Pharmaceutical Group Company Limited announced that its New Drug Application for HS-10365 capsules, a RET inhibitor for treating RET fusion-positive non-small cell lung cancer, has been accepted by China’s National Medical Products Administration. This development marks a significant step in Hansoh’s drug development efforts, potentially enhancing its position in the oncology market and offering new treatment options for lung cancer patients.
The most recent analyst rating on (HK:3692) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on innovative drug development. The company operates in the healthcare industry, with a market focus on producing treatments for various medical conditions.
Average Trading Volume: 11,925,023
Technical Sentiment Signal: Buy
Current Market Cap: HK$217.4B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.